{
     "PMID": "15740724",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20050628",
     "LR": "20151119",
     "IS": "0014-2999 (Print) 0014-2999 (Linking)",
     "VI": "510",
     "IP": "1-2",
     "DP": "2005 Mar 7",
     "TI": "Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.",
     "PG": "49-57",
     "AB": "Vilazodone has been reported to be an inhibitor of 5-hydoxytryptamine (5-HT) reuptake and a partial agonist at 5-HT1A receptors. Using [35S]GTPgammaS binding in rat hippocampal tissue, vilazodone was demonstrated to have an intrinsic activity comparable to the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). Vilazodone (1-10 mg/kg p.o.) dose-dependently displaced in vivo [3H]DASB (N,N-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine) binding from rat cortex and hippocampus, indicating that vilazodone occupies 5-HT transporters in vivo. Using in vivo microdialysis, vilazodone (10 mg/kg p.o.) was demonstrated to cause a 2-fold increase in extracellular 5-HT but no change in noradrenaline or dopamine levels in frontal cortex of freely moving rats. In contrast, administration of 8-OH-DPAT (0.3 mg/kg s.c.), either alone or in combination with a serotonin specific reuptake inhibitor (SSRI; paroxetine, 3 mg/kg p.o.), produced no increase in cortical 5-HT whilst increasing noradrenaline and dopamine 2 and 4 fold, respectively. A 2-fold increase in extracellular 5-HT levels (but no change in noradrenaline or dopamine levels) was observed after combination of the 5-HT(1A) receptor antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(pyridinyl)cyclohexanecarboxamid e) (WAY-100635; 0.3 mg/kg s.c.) and paroxetine (3 mg/kg p.o.). In summary, vilazodone behaved as a high efficacy partial agonist at the rat hippocampal 5-HT1A receptors in vitro and occupied 5-HT transporters in vivo. In vivo vilazodone induced a selective increase in extracellular levels of 5-HT in the rat frontal cortex. This profile was similar to that seen with a 5-HT1A receptor antagonist plus an SSRI but in contrast to 8-OH-DPAT either alone or in combination with paroxetine.",
     "FAU": [
          "Hughes, Zoe A",
          "Starr, Kathryn R",
          "Langmead, Christopher J",
          "Hill, Matthew",
          "Bartoszyk, Gerd D",
          "Hagan, James J",
          "Middlemiss, Derek N",
          "Dawson, Lee A"
     ],
     "AU": [
          "Hughes ZA",
          "Starr KR",
          "Langmead CJ",
          "Hill M",
          "Bartoszyk GD",
          "Hagan JJ",
          "Middlemiss DN",
          "Dawson LA"
     ],
     "AD": "Neuropharmacology Research, Psychiatry CEDD, Glaxo Smith Kline, New Frontiers Science Park, Third Avenue, Harlow, Essex, CM19 5AW, UK.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Comparative Study",
          "Journal Article"
     ],
     "PL": "Netherlands",
     "TA": "Eur J Pharmacol",
     "JT": "European journal of pharmacology",
     "JID": "1254354",
     "RN": [
          "0 (Benzofurans)",
          "0 (Benzylamines)",
          "0 (Indoles)",
          "0 (N,N-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine)",
          "0 (Piperazines)",
          "0 (Piperidones)",
          "0 (Pyridines)",
          "0 (SB 22489G)",
          "0 (Serotonin 5-HT1 Receptor Agonists)",
          "0 (Serotonin Antagonists)",
          "0 (Serotonin Receptor Agonists)",
          "0 (Serotonin Uptake Inhibitors)",
          "0 (Spiro Compounds)",
          "0 (Sulfur Radioisotopes)",
          "10028-17-8 (Tritium)",
          "333DO1RDJY (Serotonin)",
          "37589-80-3 (Guanosine 5'-O-(3-Thiotriphosphate))",
          "41VRH5220H (Paroxetine)",
          "71IH826FEG",
          "(N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxa",
          "mide)",
          "78950-78-4 (8-Hydroxy-2-(di-n-propylamino)tetralin)",
          "U8HTX2GK8J (Vilazodone Hydrochloride)",
          "VTD58H1Z2X (Dopamine)",
          "X4W3ENH1CV (Norepinephrine)"
     ],
     "SB": "IM",
     "MH": [
          "8-Hydroxy-2-(di-n-propylamino)tetralin/pharmacology",
          "Animals",
          "Benzofurans/*pharmacology",
          "Benzylamines/metabolism",
          "Binding, Competitive/drug effects",
          "Cell Membrane/drug effects/metabolism",
          "Dopamine/metabolism",
          "Dose-Response Relationship, Drug",
          "Extracellular Space/chemistry/drug effects",
          "Frontal Lobe/chemistry/*drug effects/metabolism",
          "Guanosine 5'-O-(3-Thiotriphosphate)/metabolism",
          "Hippocampus/metabolism",
          "Indoles/*pharmacology",
          "Male",
          "Microdialysis",
          "Norepinephrine/metabolism",
          "Paroxetine/pharmacology",
          "Piperazines/*pharmacology",
          "Piperidones/pharmacology",
          "Pyridines/pharmacology",
          "Rats",
          "Rats, Sprague-Dawley",
          "Serotonin/metabolism/pharmacology",
          "Serotonin 5-HT1 Receptor Agonists",
          "Serotonin Antagonists/pharmacology",
          "Serotonin Receptor Agonists/pharmacology",
          "Serotonin Uptake Inhibitors/pharmacology",
          "Spiro Compounds/pharmacology",
          "Sulfur Radioisotopes",
          "Time Factors",
          "Tritium",
          "Vilazodone Hydrochloride"
     ],
     "EDAT": "2005/03/03 09:00",
     "MHDA": "2005/06/29 09:00",
     "CRDT": [
          "2005/03/03 09:00"
     ],
     "PHST": [
          "2004/08/02 00:00 [received]",
          "2004/12/10 00:00 [revised]",
          "2005/01/13 00:00 [accepted]",
          "2005/03/03 09:00 [pubmed]",
          "2005/06/29 09:00 [medline]",
          "2005/03/03 09:00 [entrez]"
     ],
     "AID": [
          "S0014-2999(05)00041-5 [pii]",
          "10.1016/j.ejphar.2005.01.018 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Eur J Pharmacol. 2005 Mar 7;510(1-2):49-57. doi: 10.1016/j.ejphar.2005.01.018.",
     "term": "hippocampus"
}